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Introduction
Shortly after the ﬁrst cases of acquired immuno-deﬁ-
ciency syndrome (AIDS) were described in 1981 in the
United-States, two main populations at risk were identi-
ﬁed, homosexual men and haemophiliacs. Based on these
observations, the cause of AIDS was hypothesized to be
due to a sexually and blood transmitted pathogenic agent,
even before the discovery of its aetiological agent, the
human immunodeﬁciency virus (HIV). Twenty six years
later, the spread of HIV has become a global phenome-
non and infected more than 65 million people of whom
25 million are deceased, according to the latest estimates.
In 2007, 2.7 million people were newly infected, 80% of
whom were through sexual transmission.
Semen represents the main vector of HIV dissemina-
tion, evidenced by transmission occurring more efﬁciently
from men to women and men than from women to men
(Royce et al., 1997). The origin of the free viral particles
and infected cells contaminating semen are still unclear.
Semen is composed of cells and secretions from the testes,
epididymis, prostate, seminal vesicles and bulbo-urethral
glands. Because of the extreme difﬁculty in sampling the
genital organs from asymptomatic HIV+ men, the infec-
tion of the semen-producing organs has been little stud-
ied and several questions remain:
1. What is the source of virus production in the male
genital tract (MGT)? It is established that the viral strains
present in semen do not solely arise from the blood com-
partment but is⁄are the MGT organ(s) responsible for the
seminal viral load?
2. What is the nature of the interactions among HIV,
the spermatozoa and their progenitor cells the testicular
germ cells?
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Summary
Despite semen being the main vector of human immunodeﬁciency virus (HIV)
dissemination worldwide, the origin of the virus in this bodily ﬂuid remains
unclear. It was recently shown that several organs of the male genital tract
(MGT) are infected by HIV⁄simian immunodeﬁciency virus (SIV) and likely to
contribute to semen viral load during the primary and chronic stages of the
infection. These ﬁndings are important in helping answer the following ques-
tions: (i) does the MGT constitute a viral reservoir responsible for the persis-
tence of virus release into the semen of a subset of HIV-infected men under
antiretroviral therapy, who otherwise show an undetectable blood viral load? (ii)
What is the aetiology of the semen abnormalities observed in asymptomatic
HIV-infected men? (iii) What is the exact nature of the interactions between the
spermatozoa, their testicular progenitors and HIV, an important issue in the
context of assisted reproductive techniques proposed for HIV-seropositive
(HIV+) men? Answers to these questions are crucial for the design of new thera-
peutic strategies aimed at eradicating the virus from the genital tract of HIV+
men – thus reducing its sexual transmission – and for improving the care of se-
rodiscordant couples wishing to have children. This review summarizes the most
recent literature on HIV infection of the male genital tract, discusses the above
issues in light of the latest ﬁndings and highlights future directions of research.
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current anti-HIV therapy? Highly Active Antiretroviral
Therapy (HAART) does not always eradicate the virus
from semen, even when achieving an undetectable viral
load in blood and can favour the sexual transmission of
drug-resistant strains;
4. What is the cause of the semen abnormalities recently
described in HIV+ men?
Answering these questions is crucial for the design of
new therapeutic strategies aimed at eradicating the virus
from the genital tract of HIV+ men (thus reducing its
sexual transmission) and for improving the care of sero-
discordant couples wishing to have children. The aim of
this review was to summarize the current knowledge on
HIV infection of the male genital tract, discuss the above
questions in view of the latest ﬁndings and highlight
future directions of research.
Origin of HIV in semen?
HIV is present in semen as free viral particles and infected
cells. It was originally believed that the only source of HIV
in semen was infected lymphocytes and macrophages
coming from the blood. It has now been shown that the
HIV strains present in semen evolve separately from the
strains in the blood or in other anatomical compartments
(Kroodsma et al., 1994; Vernazza et al., 1994; Zhu et al.,
1996; Byrn et al., 1997; Coombs et al., 1998; Eron et al.,
1998; Hecht et al., 1998; Kiessling et al., 1998; Eyre
et al., 2000; Gupta et al., 2000; Ping et al., 2000; Ghosn
et al., 2004b; Pillai et al., 2005). This indicates that the
MGT constitutes a viral compartment distinct from the
blood and locally produces viral particles that are under a
speciﬁc selective pressure. Phylogenetic analyses showed
that the free viral particles contaminating the seminal ﬂuid
are, in some cases, distinct from those isolated from the
infected leucocytes present in semen (Paranjpe et al., 2002;
Ghosn et al., 2004b), while a subset arise because of
passive diffusion from the blood (Curran & Ball, 2002;
Ghosn et al., 2004b). In addition, a discrepancy between
the number of infected leucocytes in semen and the viral
load in the seminal plasma is often observed [reviewed in
(Dejucq & Jegou, 2001; Dejucq-Rainsford & Jegou, 2004)].
Thus it appears that the seminal lymphocytes and macro-
phages are not the only producers of the viral particles
detected in the seminal ﬂuid and that a distinct productive
source contributes to virus shedding in semen. Of interest
is that HIV shedding in semen may be intermittent, a phe-
nomenon yet to be explained and not linked to variations
in the blood viral load (Coombs et al., 1998; Gupta et al.,
2000; Bujan et al., 2004).
As infected leucocytes in semen produce viral strains
that are different from those in blood leucocytes
(Kroodsma et al., 1994; Vernazza et al., 1994; Zhu et al.,
1996; Byrn et al., 1997; Coombs et al., 1998; Eron et al.,
1998; Hecht et al., 1998; Kiessling et al., 1998; Eyre et al.,
2000; Gupta et al., 2000; Ping et al., 2000; Ghosn et al.,
2004a, 2004b; Pillai et al., 2005), this indicates that the
infected leucocytes and the free virions contaminating
semen have distinct origins within the male genital tract,
therefore suggesting that several semen-producing organs
are infected and contribute either free virus or infected
cells. The potential sources of virus in the MGT are dis-
cussed below.
HIV detection within the male genital tract organs
and cells
HIV & spermatozoa
The nature of HIV interaction with spermatozoa is still a
matter of debate (Piomboni & Baccetti, 2000). Although
the main HIV receptor CD4 is absent from spermatozoa,
several alternative receptors for HIV have been described:
GalAAG, a glycolipid related to galactosylceramide (an
alternative receptor used by HIV in conjunction with a
chemokine co-receptor to enter CD4-negative cells)
(Clapham et al., 1999), is expressed by about 30% of ejac-
ulated spermatozoa and binds the HIV envelope protein
gp120 (Brogi et al., 1998; Gadella et al., 1998). However,
this binding is inhibited by seminal plasma (Gadella et al.,
1998), suggesting that HIV could not bind to ejaculated
spermatozoa through GalAAG, although this alternative
receptor could allow HIV binding to testicular or epididy-
mal spermatozoa. The HIV co-receptor CCR5 is also
expressed by spermatozoa and could, in principle, allow
the fusion of HIV with spermatozoa if present in associa-
tion with GalAAG (Muciaccia et al., 2005a, 2005b). The
proteins and⁄or mRNAs of several other chemokine
receptors are expressed by spermatozoa (Isobe et al.,
2002; Zhang et al., 2004), some of them previously
described to mediate HIV binding. Another receptor
allowing the CD4-independent binding and entry of HIV
in other cell types (Liu et al., 2004), the mannose recep-
tor, was identiﬁed in about 10% of ejaculated spermato-
zoa and shown to bind HIV gp120 (Fanibunda et al.,
2008). No internalization of gp120 was observed and it is
presently unknown whether this receptor can trigger the
internalization of a whole virion (Fanibunda et al., 2008).
In agreement with the ﬁnding that spermatozoa express
at their surface several molecules able to bind HIV parti-
cles, puriﬁed motile spermatozoa from HIV negative
donors incubated with HIV in the absence of seminal
plasma were shown to act as carriers and transmit the
virus to susceptible leucocytes in vitro (Dussaix et al.,
1993). Using electron microscopy, different groups visual-
ized HIV particles and immuno-labelled proteins attached
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tive donors exposed to HIV in vitro (Bagasra et al., 1988;
Dussaix et al., 1993; Baccetti et al., 1994; Scoﬁeld et al.,
1994). One of them reported the detection of HIV parti-
cles in the ejaculated spermatozoa of HIV-positive men
(Baccetti et al., 1994) and their transfer to oocytes in fer-
tilization experiments in vitro (Baccetti et al., 1994) but
these results have not been conﬁrmed (Pudney et al.,
1999).
It is generally accepted that motile spermatozoa are not
productively infected by the virus. Although HIV DNA
and⁄or RNA were detected by polymerase chain reaction
(PCR) in spermatozoa puriﬁed using a gradient of Percoll
without swim-up (which further separates motile sperma-
tozoa from non-motile), these positive ﬁnding were
assumed to result from contaminations of this fraction by
a few remaining infected leucocytes or from false positives
(Dulioust et al., 1998; Marina et al., 1998; Tachet et al.,
1999; Hanabusa et al., 2000; Leruez-Ville et al., 2002a).
Indeed when PCR is performed on the highly puriﬁed
motile spermatozoa fraction isolated from semen through
a percoll gradient + swim-up or double tube techniques,
HIV nucleic acids are generally not detected (Quayle
et al., 1997; Kim et al., 1999; Hanabusa et al., 2000;
Pasquier et al., 2000; Bujan et al., 2004; Politch et al.,
2004; Kato et al., 2006; Persico et al., 2006; Bostan et al.,
2008). Of note, however, positive results were sometimes
obtained even on this highly puriﬁed spermatozoa frac-
tion (Baccetti et al., 1994; Chrystie et al., 1998), which
could result from the persistence of free viral particles
despite the washes in the presence of high seminal viral
load (Fiore et al., 2005). The early report of HIV DNA
within both motile and non-motile spermatozoa using in
situ PCR (Bagasra et al., 1994) could not be conﬁrmed by
two other teams (Pudney et al., 1999; Persico et al.,
2006). In summary, most studies failed to detect HIV
nucleic acids within puriﬁed motile spermatozoa, indicat-
ing that the few positive results reported represents either
false positives or very rare events. Of note is that only a
very small fraction of the millions of ejaculated spermato-
zoa are tested in PCR, inducing sampling biases which
may also account for the divergent results amongst stud-
ies. Interestingly, however, a recent study using a range of
techniques demonstrated the presence of HIV DNA in a
subset of ejaculated spermatozoa with an abnormal mor-
phology (Muciaccia et al., 2007) – a cell population that
had not been studied so far apart from the two early
studies, indicating HIV interaction with non-motile sper-
matozoa using electron microscopy (Scoﬁeld et al., 1994)
or in situ PCR (Bagasra et al., 1994). A phenomenon to
bear in mind in the context of HIV detection within sper-
matozoa is the fact that mammalian spermatozoa sponta-
neously take up foreign DNA or RNA in the absence of
seminal plasma (e.g. epididymal spermatozoa). Spermato-
zoa have the ability to reverse-transcribe RNA of viral ori-
gin into cDNA fragments, internalize them into sperm
nuclei (and even in some instances integrate the foreign
DNA into the sperm genome) and transfer the foreign
nucleic acids to embryos upon in vitro fertilization
(Spadafora, 1998; Giordano et al., 2000). Sperm interac-
tion with foreign nucleic acids molecules triggers endoge-
nous nucleases that cleave both exogenous and genomic
DNA, eventually leading to cell death (Spadafora, 1998).
In the context of HIV infection, one hypothesis is that
non-speciﬁc uptake of HIV RNA⁄DNA by epididymal
spermatozoa would lead to abnormal spermatozoa prone
to cell death, which may explain the detection of ejacu-
lated HIV DNA+ abnormal spermatozoa by Muciaccia
et al. (Muciaccia et al., 2007). Alternatively, this detection
may result from speciﬁc interactions between HIV and
spermatozoa.
In conclusion, spermatozoa display several receptors
that could allow HIV speciﬁc binding during their pro-
gression through the male genital tract. Thus it is likely
that spermatozoa can act as a carrier for viral particles
encountered within the testis or epididymis, i.e. in the
absence of seminal plasma, an inhibitor for some of the
HIV receptors present on spermatozoa. It is established
that spermatozoa do not produce HIV particles. Whether
they can support the early steps of HIV replication (e.g.
up to viral DNA synthesis) as proposed by some authors
remains speculative, as the vast majority of studies did
not evidence any HIV genetic material and spermatozoa
are considered as metabolically inert cells. However, non-
speciﬁc mechanisms such as foreign RNA uptake could
be at play and explain the detection of HIV DNA in a
subset of abnormal spermatozoa. The exact nature of the
interactions between HIV and spermatozoa, and their
impact on spermatozoa morphology, are far from fully
understood and require further studies.
HIV & the testis
The infection of the testis by HIV can have important
consequences for the eradication of the virus from the
MGT by antiretroviral therapies. Thus, the existence
of the blood testis barrier and of the drug efﬂux pumps
of the ABC transporter family expressed by a wide range
of testicular cell types, restrict the drug access to this
organ, as shown for some HIV replication inhibitors
(Choo et al., 2000; Livni et al., 2004). These data indicate
that, if infected, the testis may represent a viral sanctuary
resistant to antiviral treatments. To date, the concentra-
tion of HIV inhibitors in the human testis and in other
organs of the MGT is unknown. To investigate the sus-
ceptibility of the human testis to HIV infection, our team
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et al., 2006a) and revealed that the human testis is
infected by HIV-1 ex vivo and produces low levels of
infectious viral particles (Roulet et al., 2006b). The main
virus-producing cells in this culture model are the resi-
dent testicular macrophages (Roulet et al., 2006b).The
analysis of the in vivo infection of the testis in asymp-
tomatic macaques infected by SIV, the simian counterpart
of HIV, was recently undertaken. The experimental infec-
tion of cynomolgus macaques represents the best animal
model to study HIV infection as the animals display
many common features with HIV infected humans
throughout the disease progression (such as the nature of
the infected organs⁄cells and the immune responses) and
they develop AIDS like humans (Haigwood, 2004). The
in vivo study of SIV-infected macaques conﬁrmed the
productive infection of the testis during the asymptomatic
chronic stage and revealed that this infection occurs dur-
ing the acute primary infection (Le Tortorec et al.,
2008a). Infected cells within the testicular interstitial tis-
sue are macrophages and T lymphocytes, a ﬁnding in
agreement with observations in chronically-infected juve-
nile pigtail macaques (Shehu-Xhilaga et al., 2007) and in
asymptomatic HIV+ men (Muciaccia et al., 1998; Para-
njpe et al., 2002). Importantly, the presence of SIV in
some isolated testicular germ cells was shown for all the
animals tested, using both immunohistochemistry and in
situ hybridization (Le Tortorec et al., 2008a), thus rein-
forcing the previous controversial observations in maca-
ques and humans using other techniques (Muciaccia
et al., 1998; Shehu-Xhilaga et al., 2007). The spermato-
genesis and testicular morphology in chronically-infected
macaques and humans appeared normal (Muciaccia et al.,
1998; Le Tortorec et al., 2008a). A transitory increase in
the plasmatic testostestone level of chronically infected
macaques was observed, without any signiﬁcant modiﬁca-
tions of the Luteinizing Hormone (LH) level (Le Tortorec
et al., 2008a). In humans, an increase in testosterone level
was similarly reported in some chronically-infected
patients (Christeff et al., 1992). In patients with AIDS, a
decrease in circulating androgens is frequently encoun-
tered (Lo & Schambelan, 2001), which can occur in the
presence of normal or elevated LH level, indicating a
primary testicular failure. To test the hypothesis of a
direct effect of the virus on the steroidogenic function of
Leydig cells, the susceptibility of this cell type to HIV
infection in vitro was examined using a range of HIV
and SIV strains with various cell tropisms. The results
demonstrated that human Leydig cells are susceptible to
some speciﬁc HIV-2 and SIV strains but are not
infected by HIV-1 strains (Willey et al., 2003; Roulet
et al., 2006b). Thus the testosterone level modiﬁcations
in HIV-1 infected individuals are unlikely to be caused
by a direct effect of the virus on Leydig cells but more
probably result from the altered hypothalamo-pituitary
axis or, in cases where normal pituitary hormones levels
are observed, from modiﬁed cytokines production
within the testis or from direct interactions between
Leydig cells and infected macrophages (Le Tortorec
et al., 2008a).
During the later stages of the disease, the testis mor-
phology is severely damaged (Dejucq & Jegou, 2001),
with different levels of testicular germ cell degeneration
leading in some cases to a Sertoli cell only-syndrome.
This most probably results from the decrease in testoster-
one level, elevated body temperature and presence of
opportunistic infections rather than from the germ cell
infection described in some studies (Da Silva et al., 1990;
Nuovo et al., 1994; Muciaccia et al., 1998), as normal tes-
ticular morphology is observed during the asymptomatic
stage despite the association of HIV⁄SIV with testicular
germ cells.
To conclude, recent data show that the testis is infected
early during the course of HIV infection. This infection is
not associated with either any apparent change in testicu-
lar morphology or inﬂammation of the organ (Le Torto-
rec et al., 2008a). Testicular leucocytes represent the main
target cells for the virus, but testicular germ cells also
occasionally associate with HIV. This is important to bear
in mind for the practice of intra cytoplasmic sperm injec-
tion (ICSI) using testicular germ cells from HIV-infected
individuals. The presence of HIV receptors on human tes-
ticular germ cells and the molecular interactions between
these cells and HIV is currently being investigated.
Whether the testis constitutes a viral sanctuary despite an-
tiretroviral therapy is under study.
HIV & the accessory glands
Early studies showed evidence of HIV and SIV in
immune cells inﬁltrating the epididymis, prostate and
seminal vesicles of men (Da Silva et al., 1990; Pudney &
Anderson, 1991; Nuovo et al., 1994) or macaques respec-
tively (Miller et al., 1994) at the AIDS stage. But what
happens during the early and asymptomatic stages of the
disease has not been studied.
We recently analysed the infection of the epididymis,
prostate and seminal vesicles in primary- and chronically-
infected macaques. All these MGT organs are infected
very early and produce viral particles. The infection per-
sists during the chronic stage and its intensity is positively
correlated with the blood viral load. Infected cells are
mainly T lymphocytes and to a lesser extent, macro-
phages. The presence of infected leucocytes during the
chronic stage was similarly reported in the epididymis of
SIV-infected pigtail macaques (Shehu-Xhilaga et al.,
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within the stroma of the organs but are also found
inserted within the epithelium, a ﬁnding most common
within the epididymis. Their localization within the
secretory epithelium could lead to the release of free viral
particles and infected cells in the lumen and therefore in
the seminal plasma during ejaculation. In addition, the
viral particles produced within the stroma may be seques-
trated by the epithelial cells – a phenomenon described
for prostatic cells in vitro (Dezzutti et al., 2001) – and
subsequently released in the seminal ﬂuid. The chronic
infection of the accessory glands is associated with T-cell
inﬁltrations and production of inﬂammatory cytokines.
The prostate and seminal vesicles systematically displayed
higher levels of infection than the epididymis and the tes-
tis. As prostate and seminal vesicles secretions account for
respectively 30% and 60% of the seminal ﬂuid (Wolff,
1995), these two organs are likely to represent the main
source of virus in semen. In favour of this hypothesis,
prostatic massage in men was shown to signiﬁcantly
increase the seminal viral load (Smith et al., 2004). In the
same way, the previous studies indicated that vasectomy
had little effect on the semen viral load (Anderson et al.,
1991; Krieger et al., 1998), suggesting that the testis and
epididymis are minor HIV contributors in semen. We
recently conﬁrmed that the human prostate is susceptible
to HIV-1 infection ex vivo (Le Tortorec et al., 2008b).
Interestingly, the prostate was preferentially infected by
HIV-1 R5 strains (the sexually-transmitted strains) com-
pared with X4 strains, which are not sexually transmitted
and appear during the later stages of the disease
(Le Tortorec et al., 2008b).
The male genital tract – a viral reservoir?
HAART aims for durable suppression of viral load, resto-
ration and⁄or preservation of immunological function
and has dramatically enhanced the quality and life span
of the individuals who beneﬁt from these treatment.
However, the existence of viral sanctuaries prevents the
eradication of the virus in the body. A viral sanctuary is
either an anatomical (e.g. the brain) or a cellular (e.g. the
latently infected resting memory lymphocytes) site,
impermeable to the action of one or several antiviral
drugs and within which the virus replicates or persists
despite treatment. Such sanctuaries are called reservoirs
when they replenish the body in free virus or infected
cells. Thus when HAART is discontinued, the blood
plasma viral load that was undetectable under the pres-
sure of the antiretroviral drugs systematically rises again
from these reservoirs (Davey et al., 1999).
In semen, some viral inhibitors display sub-optimal
concentrations (Kashuba et al., 1999; Taylor & Pereira,
2001; Lafeuillade et al., 2002; Ghosn et al., 2004a; Chan
et al., 2008), sometimes leading to the emergence of
drug-resistant strains (Eron et al., 1998; Eyre et al., 2000;
Taylor et al., 2001, 2003; Ghosn et al., 2004a, 2004b) and
to their sexual transmission (Hecht et al., 1998; Grant
et al., 2002; Little et al., 2002; Markowitz et al., 2005).
The testis is a well-known pharmacological sanctuary into
which HIV inhibitors have restricted access (Choo et al.,
2000; Livni et al., 2004). The organ is thus a prime candi-
date for an HIV sanctuary. The fact that the rate, the
kinetic of emergence and the diversity of drug-resistant
strains diverge between the blood and the seminal plasma
(Kroodsma et al., 1994; Eron et al., 1998; Eyre et al.,
2000; Ghosn et al., 2004b; La Sala et al., 2007) strongly
suggest that HIV in semen arises from a biological com-
partment separate from blood.
Several studies indicate that the MGT may constitute a
viral reservoir responsible for HIV shedding in semen
[reviewed in (Dejucq & Jegou, 2001; Dejucq-Rainsford &
Jegou, 2004)]. Although in most patients HAART can
reduce the semen viral load to an undetectable level (Liuzzi
et al., 1999; Barroso et al., 2000; Vernazza et al., 2000;
Leruez-Ville et al., 2002b; Bujan et al., 2004; Chan et al.,
2008; Ghosn et al., 2008), the persistence of HIV RNA
and⁄or infected cells in semen has been reported in up to
10% of men under various antiretroviral treatment combi-
nations, despite an undetectable blood viral load (Kiessling
et al., 1998; Zhang et al., 1998; Dornadula et al., 1999;
Mayer et al., 1999; Lafeuillade et al., 2002; Leruez-Ville
et al., 2002b; Solas et al., 2003; Vernazza et al., 2007; Marc-
elin et al., 2008). Most recently, an even higher percentage
of men shedding HIV in semen despite effective HAART
has been reported: 4 months following the initiation of
HAART, 48% of 25 individuals with suppressed blood viral
load were releasing HIV in semen and for 16% of them at a
high level. Strikingly, this persistent shedding was still
observed for 31% of 13 individuals under effective HAART
for a median of 10 years (Sheth et al., 2009). The residual
viral load detected in semen is generally low but appears to
be extremely variable amongst individuals (range of 0.6 log
to 5 log of HIV RNA copies⁄mL) (Dornadula et al., 1999;
Mayer et al., 1999; Vernazza et al., 2000; Leruez-Ville et al.,
2002b; Bujan et al., 2004; Marcelin et al., 2008; Pasquier
et al., 2008).
This persistence of HIV excretion in the semen of a
subset of individuals under HAART has potentially
important consequences for the transmission of the virus.
The critical inoculum for sexual transmission is unknown.
A mathematical model indicated a very low risk of het-
erosexual transmission of three of 10 000 episodes of
intercourse for 3 Log of HIV RNA copies per ejaculate
(Chakraborty et al., 2001) and HIV heterosexual trans-
mission was estimated to decrease by about 80% follow-
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been raised as to whether natural conception is an accept-
able⁄negligible risk option for HIV-serodiscordant couples
in whom the HIV+ partner is effectively treated (Barreiro
et al., 2007) and recently, the Swiss national AIDS Com-
mission stated that serodiscordant couples in whom the
infected partner had an undetectable blood viral load
under prolonged HAART could safely have unprotected
intercourses in the absence of other sexually transmitted
infections (STIs) (Vernazza et al., 2008) – a factor known
to increase HIV shedding in semen (Dejucq-Rainsford &
Jegou, 2004; Zuckerman et al., 2009). This statement has
generated a heated debate amongst scientists and patients’
associations. A mathematical model calculated that HIV
incidence would quadruple if this advice was followed by
10 000 couples over 10 years (Wilson et al., 2008). It
appears from the literature that although drastically
reduced, the possibility of transmitting HIV despite an
undetectable blood viral load following HAART remains
in a subset of patients, as recently illustrated by the case
report of an homosexual man under effective HAART
who contaminated his partner (Sturmer et al., 2008).
In conclusion, the fact that HIV may persist and shed
intermittently in semen from men under effective HAART
free of other STIs (Bujan et al., 2004; Marcelin et al.,
2008) reinforces the need for testing not only the blood
viraemia but also the seminal viral load and this in sev-
eral distant measurements, to assess the level of risk of a
sexual transmission of each individual under HAART. It
also stresses the importance of determining the nature of
the reservoirs responsible for HIV shedding in semen, to
design more effective therapeutic strategies that can eradi-
cate the virus from semen.
HIV and male reproduction
In 2008, the majority of the 33 million HIV-infected peo-
ple worldwide were in their reproductive years. The HIV
seropositive male partner of a growing number of sero-
discordant couples is seeking assisted reproductive tech-
niques (ART) to have children without contaminating the
partner and embryo. ART uses spermatozoa isolated from
the infected components in semen (infected immune cells
and seminal ﬂuid) and tested negative for viral
DNA⁄RNA (reviewed in (Englert et al., 2004; Bujan et al.,
2007a)). Semen quality is an essential criterion for inclu-
sion (as an important number of spermatozoa have to be
tested) and this represents a limiting factor for many cou-
ples. The semen parameters of HIV+ men have been
analysed by several teams. In all studies except one (Garr-
ido et al., 2005), a trend towards semen degradation was
observed in men at the advanced stage of the disease with
low CD4 + T lymphocytes number in blood (Krieger
et al., 1991a, 1991b; Crittenden et al., 1992; Politch et al.,
1994; Dondero et al., 1996; Lasheeb et al., 1997; Muller
et al., 1998). As for asymptomatic HIV+ men in the
chronic stage, most studies, apart from two (Krieger
et al., 1991a, 1991b; Garrido et al., 2005), reported vari-
ous abnormalities: spermatozoa reduced motility,
decreased total number and⁄or increased morphological
abnormal forms (Crittenden et al., 1992; Dondero et al.,
1996; Muller et al., 1998; Dulioust et al., 2002; Nicopoul-
los et al., 2004; Bujan et al., 2007b; La Sala et al., 2007),
lower volume of the ejaculate (Muller et al., 1998; Duli-
oust et al., 2002; Nicopoullos et al., 2004; Bujan et al.,
2007b; La Sala et al., 2007), increased pH of the ejaculate
(Bujan et al., 2007b), increased number of round cells in
the seminal ﬂuid (Crittenden et al., 1992; Dulioust et al.,
2002). The most common ﬁndings in recent studies were
a decrease in spermatozoa motility and ejaculate volume
in healthy HIV+ men (Dulioust et al., 2002; Nicopoullos
et al., 2004; Bujan et al., 2007b). An elevated rate of
spontaneous abortions was reported in serodiscordant
couples of whom the man is HIV+ (Sergerie et al., 2004).
Of note is that the majority of these men are taking anti-
retroviral drugs which may affect semen quality, indepen-
dently or in addition to the infection. The nucleosidic
inhibitors of reverse transcriptase (NRTI), in particular
thymidine analogues, are suspected to generate modiﬁca-
tions of mitochondrial DNA, which could affect sperma-
tozoa motility (Sergerie et al., 2004; La Sala et al., 2007).
Recently, a study examined the semen parameters of
HIV+ men before and after the initiation of different
combination of antiretroviral therapies (van Leeuwen
et al., 2008b). A decrease in motile spermatozoa was
observed as early as 4 weeks post-treatment initiation,
while the semen quality was stable over 1.5 years in
untreated HIV+ men (van Leeuwen et al., 2008b),
suggesting a direct effect of the antiretroviral drugs on
spermatozoa motility. Surprisingly, this effect was
observed to be independent of the use of thymidine ana-
logues (van Leeuwen et al., 2008b). – Importantly, the
semen volume was unchanged following treatment but
was in the lower normal range (van Leeuwen et al.,
2008a, 2008b). Further studies will be crucial to the eluci-
dation of the mechanisms responsible for the semen
parameter deterioration observed in healthy asymptom-
atic HIV+ men.
Conclusions
Deciphering the origins of HIV in semen is crucial to the
development of targeted therapeutic strategies aimed at
eradicating the virus in semen. It was recently revealed
that MGT organs are infected by HIV during the acute
and asymptomatic chronic stages of HIV infection. These
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the semen viral load.
Future research should be directed to the following
areas: (i) determining whether one or several of the
infected MGT organs constitute a viral reservoir, which
could explain the persistence of HIV in the semen of
men under effective treatment with undetectable blood
viral load; (ii) determining the aetiology of the semen
parameter modiﬁcations in HIV+ men under HAART;
(iii) deciphering the exact nature of the interactions
between HIV, the testicular germ cells and the spermato-
zoa, both important issues in the context of ART; (iv)
analysing the effect of HIV infection on the seminal
plasma composition and its impact on HIV infectivity,
which may reveal new mechanisms that could be useful
in the ﬁght against the AIDS pandemic as a few studies
suggest that seminal plasma factors may inﬂuence HIV
sexual transmission.
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